Author Archives: greensplash

  1. Professor Tomáš Hanke speaks to Scientia about innovative methods in vaccine design and development to combat HIV.

    Leave a Comment

    Prof Hanke, EAVI2020 PI at the University of Oxford spoke to Scientia which included his work on T cell response to second-generation conserved immunogen, HIVconsvX, and its predecessor, HIVconsv. Scientia is a popularised outreach journal that provides researchers with a platform to communicate their findings to others outside their speciality. Technical nomenclature is often transcribed into easier formats allowing further reach of the scientific outputs for maximising social impact, and engaging stakeholders.

    Read the full article at the Scientia website.

    Professor Tomáš Hanke – Use of Experimental Medicine for Rational Development of an Effective HIV Vaccine

    Aug 12, 2020 | BiologyHealth and Medicine


    screenshot of Scientia article on website

  2. EAVI2020 to Host Satellite Workshop at HIVR4P 2018

    Leave a Comment

    Our Consortium members are delighted to have been given the opportunity to host a Satellite Session at this year’s HIVR4P Conference taking place in Madrid, Spain. This is a prestigious event which attracts international recognition from leaders in the field of HIV and AIDS research. The workshop ‘Human Centric Vaccine Discovery’ will feature talks from key members of our Consortium, including our coordinating Principal Investigator Professor Robin Shattock (Imperial College London).

    Date: Monday 22nd October 2018
    Time: 12:00 – 15:00
    Room: Marsella

    For further information please view our Satellite Session Agenda.

  3. EAVI2020’s kick-off meeting at Imperial College London

    Leave a Comment

    Imperial College hosted EAVI2020 ‘s kick-off meeting in London on Thursday 26th November 2015.

    Representatives from the project’s partner institutions travelled to London to attend the kick-off meeting of this exciting new initiative, which aims to develop HIV vaccine candidates that can be taken to human trials within five years.

    “Our approach to accelerate HIV vaccine concepts is unique”

    Some of the world’s best experts in the field of vaccine design and delivery gathered to discuss the first steps to start the new HIV vaccine development.

    Prof Robin Shattock, Imperial College, pointed out that “our approach to accelerate HIV vaccine concepts is unique. This is a flagship project for HIV vaccine research”.

    More information

    Please follow our most recent news and developments in our Twitter and Facebook accounts.

    For more information about EAVI2020, please contact us.

  4. EAVI2020 presented as a successful case study in the Health Tech 2020 event, 29th October 2015

    Leave a Comment

    In response to circa 2 billion euros of Health and ICT innovation-based funding about to be launched by the European Commission, Vision 2020: The Horizon Network hosted London’s Horizon 2020 Health-Tech event on 29 and 30 October 2015.

    The Health-Tech 2020 event was held at London’s prestigious City Hall and themed around Horizon 2020 success (day 1), and thematic discuss/network around the upcoming H2020 calls collaborations (day 2).

    EAVI2020 – Case study for a successful Horizon2020 proposal

    Prof Robin Shattock, Chair in Mucosal Infection and Immunity at Imperial College and coordinator of EAVI2020, presented the EAVI2020 project, which at the time had not had its kick-start date yet. The presentation focused on all the steps the consortium took during the proposal stage in order to make this a successfully funded Horizon2020 proposal.

    Prof. Shattock also participated in the Panel discussion on Horizon2020 Opportunities along with representatives of other universities and private companies.

    More information

    Go to the Vision2020 website for more information on the Vision2020 network and the HealthTech2020 event.

    For more information about EAVI2020, please contact us.

  5. HIV scientists launch 23 million euro project to develop vaccine

    Leave a Comment

    A new 23 million euro initiative to accelerate the search for an effective HIV vaccine begins today.

    Financed by the European Commission, the European AIDS Vaccine Initiative (EAVI2020) brings together leading HIV researchers from public organisations and biotech companies from across Europe, Australia, Canada and the USA in a focused effort to develop protective and therapeutic HIV vaccines.

    According to the World Health Organisation, around 35 million people were living with HIV at the end of 2013. Over two million people are newly infected every year, and it is estimated that around 22 billion US dollars is spent yearly on HIV treatment and care. An effective vaccine remains the best hope of ending the epidemic.

    Although researchers have been working on developing a vaccine for 30 years, recent advances are helping to speed up their quest. Scientists have isolated antibodies that are able to block HIV infection in preclinical models, and there have been new developments in using synthetic biology to design better vaccines.

    The EAVI2020 consortium, which is led by Imperial College London, unites scientists from 22 institutions, pooling their knowledge and expertise to develop novel candidate vaccines that can be taken through to human trials within five years. EAVI2020 is funded with an EU-grant under the health program of Horizon 2020 for research and innovation.

    Professor Robin Shattock, Coordinator of EAVI2020, from the Department of Medicine at Imperial College London, said: “Creating an effective vaccine against HIV represents one of the greatest biological challenges of a generation. This project creates an unique opportunity for us to build on the enormous scientific progress gleaned over the last few years, providing an unprecedented insight into the nature of protective antibodies and anti-viral cellular response that will be needed for an effective vaccine. We now understand much more about how humans make protective immune responses and how to structure vaccine candidates. We have a level of understanding at a molecular level that was not previously available.

    “But it is impossible for one group or institution to create an HIV vaccine on its own. This new project should enable us to move much more quickly. It brings together a multidisciplinary team of molecular biologists, immunologists, virologists, biotechnologists and clinicians, providing the breadth of expertise needed to take the latest discoveries in the lab and rapidly advance them through preclinical testing and manufacture, into early human trials.”

    At Imperial, researchers will be looking at how healthy human volunteers’ immune systems respond to potential vaccines, studying the antibodies that the volunteers produce. The researchers will explore the pathways in the body that make these antibodies, in order to fine-tune candidate vaccines.

    Dr Ruxandra Draghia-Akli, Director of the Health Directorate at the Directorate General for Research and Innovation of the European Commission said” In its dual role of policy maker and research funder, the European Commission has played an essential part for over thirty years in supporting HIV vaccine research. Despite major global investments in the field and the promising progress, several scientific obstacles have to be overcome to develop novel promising HIV vaccine candidates. It is with this in mind that the European Commission is providing an almost 23 million Euro grant to the EAVI2020 consortium from which we have high hopes for success. This will allow European scientists to work together and in collaboration with researchers from outside Europe to successfully develop predictive tools and better vaccine candidates to be tested at an early stage of the process”.

    Disclaimer: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 681137